NephResults develops disease‑tailored biosensor platforms combined with AI‑driven signal analytics to deliver patient‑centered solutions for kidney diseases. By integrating clinical characteristics into its biosensing technology, the company enables clinicians to monitor renal function more accurately and identify therapeutic opportunities earlier.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic kidney diseases such as focal segmental glomerulosclerosis (FSGS) lack precise, real‑time tools to monitor renal function and assess therapeutic response, leading to delayed treatment adjustments and suboptimal outcomes.
Solution
NephResults creates disease‑specific biosensor platforms that incorporate patients’ clinical characteristics into the sensing hardware. The biosensors generate physiological signals related to kidney function, which are processed by AI‑driven analytics to provide continuous, quantitative readouts. Real‑time interpretation of these data supports clinicians in making personalized treatment decisions and identifying therapeutic opportunities earlier. By focusing on cost‑effectiveness and regulatory compliance, the solution aims to integrate seamlessly into existing diagnostic workflows and improve patient management for chronic kidney conditions.
Target Audience
Primary customers are nephrologists and renal care centers seeking precise monitoring tools for patients with chronic kidney diseases, particularly those managing FSGS.
Features
- Biosensor devices calibrated for specific kidney disease phenotypes, including FSGS
- Integration of patient clinical data (e.g., biomarkers, demographics) into sensor calibration
- AI models that perform real‑time signal processing and predictive analytics
- Continuous monitoring outputs presented as actionable metrics for clinicians
- Designed for cost‑effective deployment in clinical settings while meeting compliance standards